1
|
Heuer JG, Meyer CM, Baker HE, Geiser A, Lucchesi J, Xu D, Hamang M, Martin JA, Hu C, Roth KD, Thirunavukkarasu K, Alsina-Fernandez J, Ma YL. Pharmacological Evaluation of a Pegylated Urocortin-1 Peptide in Experimental Autoimmune Disease Models. J Pharmacol Exp Ther 2022; 382:287-298. [PMID: 35688476 DOI: 10.1124/jpet.122.001151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Accepted: 05/25/2022] [Indexed: 11/22/2022] Open
Abstract
Urocortin-1 (UCN1) is a member of the corticotropin releasing hormone (CRH) family of peptides that acts through CRH-receptor 1 (CRHR1) and CRH-receptor 2 (CRHR2). UCN1 can induce adrenocorticotropin hormone (ACTH) and downstream glucocorticoids through CRHR1 and promote beneficial metabolic effects through CRHR2. UCN1 has a short half-life and has been shown to improve experimental autoimmune disease. A pegylated UCN1 peptide (PEG-hUCN1) was generated to extend half-life and was tested in multiple experimental autoimmune disease models and in healthy mice to determine effects on corticosterone induction, autoimmune disease, and glucocorticoid induced adverse effects. Cardiovascular effects were also assessed by telemetry. PEG-hUCN1 demonstrated a dose dependent 4-to-6-fold elevation of serum corticosterone and significantly improved autoimmune disease comparable to prednisolone in several experimental models. In healthy mice, PEG-hUCN1 showed less adverse effects compared to corticosterone treatment. PEG-hUCN1 peptide induced an initial 30% reduction in blood pressure that was followed by a gradual and sustained 30% increase in blood pressure at the highest dose. Additionally, an adeno-associated viral 8 (AAV8) UCN1 was used to assess adverse effects of chronic elevation of UCN1 in wild type and CRHR2 knockout mice. Chronic UCN1 expression by an AAV8 approach in wild type and CRHR2 knockout mice demonstrated an important role of CRHR2 in countering the adverse metabolic effects of elevated corticosterone from UCN1. Our findings demonstrate that PEG-hUCN1 shows profound effects in treating autoimmune disease with an improved safety profile relative to corticosterone and that CRHR2 activity is important in metabolic regulation. Significance Statement This study reports the generation and characterization of a pegylated UCN1 peptide and the role of CRHR2 in UCN1-induced metabolic effects. The potency/selectivity, pharmacokinetic properties, pharmacodynamic effects and efficacy in four autoimmune models and safety profiles are presented. This pegylated UCN1 shows potential for treating autoimmune diseases with reduced adverse effects compared to corticosterone treatment. Continuous exposure to UCN1 through an AAV8 approach demonstrates some glucocorticoid mediated adverse metabolic effects that are exacerbated in the absence of the CRHR2 receptor.
Collapse
Affiliation(s)
- Josef G Heuer
- Biotherapeutic Discovery Research, Eli Lilly and Company, United States
| | - Catalina M Meyer
- Biotherapeutic Discovery Research, Eli Lilly and Company, United States
| | - Hana E Baker
- Lilly Research Laboratories, Eli Lilly and Company, United States
| | - Andrea Geiser
- New Therapeutic Modalities, Eli Lilly and Company, United States
| | - Jonathan Lucchesi
- Biotechnology & Immunology Res, Eli Lilly and Company, United States
| | - Daniel Xu
- Biotechnology & Immunology Res, Eli Lilly and Company, United States
| | - Matthew Hamang
- Biotechnology & Immunology Res, Eli Lilly and Company, United States
| | | | - Charlie Hu
- Biotherapeutic Discovery Research, Eli Lilly and Company, United States
| | - Kenneth D Roth
- Molecular Pharmacology, Eli Lilly and Company, United States
| | | | | | - Yanfei L Ma
- Biotechnology & Immunology Res, Eli Lilly and Company, United States
| |
Collapse
|
2
|
Hoffmann DB, Komrakova M, Pflug S, von Oertzen M, Saul D, Weiser L, Walde TA, Wassmann M, Schilling AF, Lehmann W, Sehmisch S. Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis. J Bone Miner Metab 2019; 37:243-255. [PMID: 29785666 DOI: 10.1007/s00774-018-0929-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Accepted: 04/17/2018] [Indexed: 01/05/2023]
Abstract
Selective androgen receptor modulators (SARMs) have shown beneficial effects on muscle wasting, general physical function and bone properties in male mammals. However, data on the effects of SARMs in postmenopausal osteoporotic bone are scarce. We evaluated the effects of the SARM drug ostarine on postmenopausal osteoporotic bone in a rat osteoporosis model. Ovariectomy was performed on 46 of 56 3-month-old female Sprague-Dawley rats. Eight weeks after ovariectomy, ostarine was orally administered daily for 5 weeks in dosages of 0.04 (low, OVX + Ost. 0.04), 0.4 (intermediate, OVX + Ost. 0.4), and 4 mg/kg (high, OVX + Ost. 4) body weight. Another ovariectomized group received no ostarine. Lumbar vertebrae and femora were removed for biomechanical, gene expression, ashing, and computer tomography analyses. Low dose showed no effects. The effects of intermediate and high doses were comparable overall. Improvements were mainly seen in structural properties such as bone mineral density and bone volume density. However, the effects in femora were superior to effects in vertebrae. Ostarine treatment for 5 weeks did not improve significantly biomechanical properties. mRNA expression of the receptor activator of NF-κB ligand decreased after treatment, and uterine weight increased. Serum levels of phosphorus increased following ostarine treatment in intermediate and high-dose groups. Short-term treatment of osteoporotic bone with ostarine leads to improvement of several microstructural bone indices. While we did not observe changes in biomechanics, it is conceivable that longer treatment may also improve biomechanical properties. Further studies are needed to characterize longer time effects and side effects of ostarine in osteoporosis.
Collapse
Affiliation(s)
- D B Hoffmann
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany.
| | - M Komrakova
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - S Pflug
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - M von Oertzen
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - D Saul
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - L Weiser
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - T A Walde
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - M Wassmann
- Department of Medical Microbiology, Subdivision of General Hygiene and Environmental Health, University of Goettingen, Humboldallee 34a, 37073, Goettingen, Germany
| | - A F Schilling
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - W Lehmann
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - S Sehmisch
- Department of Trauma-, Orthopaedic- and Plastic Surgery, University Medical Center Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| |
Collapse
|
3
|
Saul D, Weber M, Zimmermann MH, Kosinsky RL, Hoffmann DB, Menger B, Taudien S, Lehmann W, Komrakova M, Sehmisch S. Effect of the lipoxygenase inhibitor baicalein on bone tissue and bone healing in ovariectomized rats. Nutr Metab (Lond) 2019; 16:4. [PMID: 30651746 PMCID: PMC6329162 DOI: 10.1186/s12986-018-0327-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Accepted: 12/10/2018] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Osteoporosis is one of the world's major medical burdens in the twenty-first century. Pharmaceutical intervention currently focusses on decelerating bone loss, but phytochemicals such as baicalein, which is a lipoxygenase inhibitor, may rescue bone loss. Studies evaluating the effect of baicalein in vivo are rare. METHODS We administered baicalein to sixty-one three-month-old female Sprague-Dawley rats. They were divided into five groups, four of which were ovariectomized (OVX) and one non-ovariectomized (NON-OVX). Eight weeks after ovariectomy, bilateral tibial osteotomy with plate osteosynthesis was performed and bone formation quantified. Baicalein was administered subcutaneously using three doses (C1: 1 mg/kg BW; C2: 10 mg/kg BW; and C3: 100 mg/kg BW) eight weeks after ovariectomy for four weeks. Finally, femora and tibiae were collected. Biomechanical tests, micro-CT, ashing, histological and gene expression analyses were performed. RESULTS Biomechanical properties were unchanged in tibiae and reduced in femora. In tibiae, C1 treatment enhanced callus density and cortical width and decreased callus area. In the C3 group, callus formation was reduced during the first 3 weeks after osteotomy, correlating to a higher mRNA expression of Osteocalcin, Tartrate-resistant acid phosphatase and Rankl. In femora, baicalein treatments did not alter bone parameters. CONCLUSIONS Baicalein enhanced callus density and cortical width but impaired early callus formation in tibiae. In femora, it diminished the biomechanical properties and calcium-to-phosphate ratio. Thus, it is not advisable to apply baicalein to treat early bone fractures. To determine the exact effects on bone healing, further studies in which baicalein treatments are started at different stages of healing are needed.
Collapse
Affiliation(s)
- Dominik Saul
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Marie Weber
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Marc Hendrik Zimmermann
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Robyn Laura Kosinsky
- Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Daniel Bernd Hoffmann
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Björn Menger
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Stefan Taudien
- Division of Infection Control and Infectious Diseases, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Wolfgang Lehmann
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Marina Komrakova
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| | - Stephan Sehmisch
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany
| |
Collapse
|
4
|
Saul D, Geisberg LK, Gehle T, Hoffmann DB, Tezval M, Sehmisch S, Komrakova M. Changes in Musculoskeletal System and Metabolism in Osteoporotic Rats Treated With Urocortin. Front Endocrinol (Lausanne) 2019; 10:400. [PMID: 31293517 PMCID: PMC6601316 DOI: 10.3389/fendo.2019.00400] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Accepted: 06/06/2019] [Indexed: 01/30/2023] Open
Abstract
Objective: In aging population, postmenopausal osteoporosis and decline of musculoskeletal function, referred to as "frailty syndrome" lead to loss of bone and muscle, causing falls, and fall-related injuries. To limit the impact of this portentous duo, simultaneous treatment of both is needed. Urocortin (UCN) has been reported to improve osteoporotic bone properties while its effect on muscle has not been addressed yet. Design and Methods: We aimed to investigate the effect of urocortin in vivo on skeletal muscle structure in osteopenic rats. Sixty Sprague-Dawley rats were divided into five groups: four were ovariectomized (OVX) and one underwent sham operation (SHAM). One ovariectomized group was left untreated (OVX), while one was treated with urocortin s.c. in 3 μg/kg body weight (bw) (OVX+UCN low), one with 30 μg/kg (OVX+UCN high), while one group was treated with estradiol orally (OVX+E: 0.2 mg/kg bw), each for 35 days. Mm. gastrocnemius, longissimus, and soleus were isolated and capillary density as well as diameters of type I and II fibers were measured. In addition, we examined the effect of UCN on tibia using biomechanical, micro-CT and ashing analysis and investigated the blood serum. Results: We demonstrated a positive effect of UCN on M. soleus, in which fiber diameter was positively influenced. The biomechanical and structural parameters of bone were not changed in UCN treated rats. The higher cholesterol, glucose and triglyceride levels in the "UCN high" group raise concern about this treatment. Conclusions: Our results portray urocortin as a substance that can be assessed for future therapeutic treatments of estrogen deficiency. New and Noteworthy: Urocortin has a positive effect on M. soleus (diameter). Urocortin raises serum cholesterol and triglyceride levels. Bone tissue was not affected by UCN.
Collapse
Affiliation(s)
- Dominik Saul
- Department of Trauma, Orthopedics and Reconstructive Surgery, Georg-August-University of Göttingen, Göttingen, Germany
| | - Laura Katharina Geisberg
- Department of Trauma, Orthopedics and Reconstructive Surgery, Georg-August-University of Göttingen, Göttingen, Germany
| | - Torben Gehle
- Department of Trauma, Orthopedics and Reconstructive Surgery, Georg-August-University of Göttingen, Göttingen, Germany
| | - Daniel Bernd Hoffmann
- Department of Trauma, Orthopedics and Reconstructive Surgery, Georg-August-University of Göttingen, Göttingen, Germany
| | - Mohammad Tezval
- Klinik für Unfallchirurgie, Sporttraumatologie und Handchirurgie, Klinikum Vest, Recklinghausen, Germany
| | - Stephan Sehmisch
- Department of Trauma, Orthopedics and Reconstructive Surgery, Georg-August-University of Göttingen, Göttingen, Germany
| | - Marina Komrakova
- Department of Trauma, Orthopedics and Reconstructive Surgery, Georg-August-University of Göttingen, Göttingen, Germany
- *Correspondence: Marina Komrakova ; orcid.org/0000-0002-6225-4378
| |
Collapse
|
5
|
Saul D, Ninkovic M, Komrakova M, Wolff L, Simka P, Gasimov T, Menger B, Hoffmann DB, Rohde V, Sehmisch S. Effect of zileuton on osteoporotic bone and its healing, expression of bone, and brain genes in rats. J Appl Physiol (1985) 2017; 124:118-130. [PMID: 28860177 DOI: 10.1152/japplphysiol.01126.2016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Estrogen deficiency and aging are associated with osteoporosis, impaired bone healing, and lower cognitive performance. Close functional and physical connections occur between bone and the central nervous system. An anti-inflammatory drug, zileuton (which is an inhibitor of arachidonate 5-lipoxygenase), is known to have a positive effect on bone tissue repair and brain ischemia. We studied the effect of zileuton on osteopenic bone and its healing and on the genes considered to be crucial for the cross talks between bone and brain. Three-month-old Sprague-Dawley rats were ovariectomized or left untreated. After 8 wk, bilateral metaphyseal tibia osteotomy with plate osteosynthesis was performed in all rats. Ovariectomized rats were fed with food containing zileuton (1, 10, or 100 mg/kg body wt) for 5 wk. In tibiae, bone volume, callus and cortical volume, and gene expression of osteocalcin and alkaline phosphatase were enhanced by zileuton (10 or 100 mg); biomechanical properties and bone density were not changed. In femur, zileuton enlarged cortical volume distal and trabecular volume proximal, decreasing their density. The expression level of brain Sema3a, known to regulate bone mass positively, was downregulated after ovariectomy. In contrast, bone Sema4d, a negative regulator of bone mass, was upregulated in the tibia callus after ovariectomy, whereas zileuton treatment (10 or 100 mg) resulted in reverse effects. Here, we describe for the first time the expression of Rbbp4 mRNA and its increase in tibia after ovariectomy. Zileuton caused downregulation of Rbbp4 in the hippocampus and had an effect on bone healing, changed the expression of genes involved in cross talk between bones and brain, and may be a potent drug for further examination in estrogen deficiency-related dysfunction(s). NEW & NOTEWORTHY Zileuton, a 5-lipoxygenase inhibitor, increased bone volume, callus and cortical volume in osteotomized tibia, and trabecular and cortical volume in femur. Although the expression of Sema3a (positively regulating bone mass) in brain was downregulated and Sema4d (negatively regulating bone mass) was upregulated in tibia callus after ovariectomy, zileuton could counteract these effects. Rbbp4 (involved in age-related memory loss) was increased in tibia callus after ovariectomy.
Collapse
Affiliation(s)
- D Saul
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen , Göttingen , Germany
| | - M Ninkovic
- Department of Neurosurgery, University Medical Center Göttingen , Göttingen , Germany
| | - M Komrakova
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen , Göttingen , Germany
| | - L Wolff
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen , Göttingen , Germany
| | - P Simka
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen , Göttingen , Germany
| | - T Gasimov
- Department of Neurosurgery, University Medical Center Göttingen , Göttingen , Germany
| | - B Menger
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen , Göttingen , Germany
| | - D B Hoffmann
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen , Göttingen , Germany
| | - V Rohde
- Department of Neurosurgery, University Medical Center Göttingen , Göttingen , Germany
| | - S Sehmisch
- Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University Medical Center Göttingen , Göttingen , Germany
| |
Collapse
|
6
|
Hoffmann DB, Sehmisch S, Hofmann AM, Eimer C, Komrakova M, Saul D, Wassmann M, Stürmer KM, Tezval M. Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis. J Bone Miner Metab 2017; 35:31-39. [PMID: 26825660 DOI: 10.1007/s00774-016-0736-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Accepted: 12/24/2015] [Indexed: 02/01/2023]
Abstract
We investigated the combinatorial effects of whole-body vertical vibration (WBVV) with the primarily osteoanabolic parathyroid hormone (PTH) and the mainly antiresorptive strontium ranelate (SR) in a rat model of osteoporosis. Ovariectomies were performed on 76 three-month-old Sprague-Dawley rats (OVX, n = 76; NON-OVX, n = 12). After 8 weeks, the ovariectomized rats were divided into 6 groups. One group (OVX + PTH) received daily injections of PTH (40 µg/kg body weight/day) for 6 weeks. Another group (OVX + SR) was fed SR-supplemented chow (600 mg/kg body weight/day). Three groups (OVX + VIB, OVX + PTH + VIB, and OVX + SR + VIB) were treated with WBVV twice a day at 70 Hz for 15 min. Two groups (OVX + PTH + VIB, OVX + SR + VIB) were treated additionally with PTH and SR, respectively. The rats were killed at 14 weeks post-ovariectomy. The lumbar vertebrae and femora were removed for biomechanical and morphological assessment. PTH produced statistically significant improvements in biomechanical and structural properties, including bone mineral density (BMD) and trabecular bone quality. In contrast, SR treatment exerted mild effects, with significant effects in cortical thickness only. SR produced no significant improvement in biomechanical properties. WBVV as a single or an adjunctive therapy produced no significant improvements. In conclusion, vibration therapy administered as a single or dual treatment had no significant impact on bones affected by osteoporosis. PTH considerably improved bone quality in osteoporosis cases and is superior to treatment with SR.
Collapse
Affiliation(s)
- D B Hoffmann
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany.
| | - S Sehmisch
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - A M Hofmann
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - C Eimer
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - M Komrakova
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - D Saul
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - M Wassmann
- Medical Institute of General Hygiene and Environmental Health, University of Goettingen, Kreuzbergring No. 57, 37075, Goettingen, Germany
| | - K M Stürmer
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| | - M Tezval
- Department of Trauma and Reconstructive Surgery, University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany
| |
Collapse
|